Clinical Trial Update: AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing AZD6244 (selumetinib) to Capecitabine in patients with advanced or metastatic pancreatic cancer after failure of first-line gemci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• AZD6244 (selumetinib) (selumetinib)
• Xeloda (capecitabine) (capecitabine)

Snippet

Sponsor: AstraZeneca | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED